The company has received tentative approval from the United States Food and Drug Administration (USFDA) for Sitagliptin tablets in strengths of 25 mg, 50 mg, and 100 mg, Zydus Cadila said in a BSE filing.
It said the drug will be produced at the group's formulations facility at SEZ, Ahmedabad.
The group has more than 217 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs).
Shares of Cadila Healthcare, the listed entity of the group, were trading 0.59 per cent lower at Rs 418.30 per scrip on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)